Literature DB >> 7427046

Removal of metronidazole by haemodialysis.

R Gabriel, C M Page, J Collier, G W Houghton, R Templeton, P S Thorne.   

Abstract

The removal of the anti-anaerobic antibiotic metronidazole has been studied in oliguric patients. The drug and its principal metabolite are rapidly removed by haemodialysis so that the plasma concentration quickly falls below the therapeutic range. Hence a further dose of metronidazole would be needed after dialysis to restore an adequate plasma concentration.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7427046     DOI： 10.1002/bjs.1800670807

Source DB:  PubMed          Journal:  Br J Surg        ISSN： 0007-1323            Impact factor:   6.939


  6 in total

1.  Physiologic assessment of the four commonly performed endorectal pullthroughs.

Authors:  D K Stoller; A G Coran; R A Drongowski; E R Bank; G D Abrams
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  D R Guay; R C Meatherall; H Baxter; W R Jacyk; B Penner
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 4.  Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.

Authors:  C S Lee; T C Marbury
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

5.  Pharmacokinetics of metronidazole in patients with varying degrees of renal failure.

Authors:  G W Houghton; M J Dennis; R Gabriel
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

6.  Hemodialysis clearance of metronidazole and its metabolites.

Authors:  A H Lau; C W Chang; S Sabatini
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.